Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
Impressive progress has recently been made in the field of cancer immunotherapy with the adoptive transfer of T cells, a successful personalized strategy, and checkpoint inhibitors (CPI) having extended the survival of numerous patients. However, not all patients have been able to benefit from these...
Guardado en:
Autores principales: | Lana E. Kandalaft, Alexandre Harari |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b0195ac1934943c8b8cff9c93cc36a18 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
por: Alexandre Harari, et al.
Publicado: (2021) -
TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
por: Salazar-Onfray,Flavio, et al.
Publicado: (2013) -
Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
por: Maria Poplawska, et al.
Publicado: (2021) -
A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model
por: Soliman H, et al.
Publicado: (2015) -
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
por: Elena V. Abakushina, et al.
Publicado: (2021)